Zortress (Everolimus) to Prevent Alloantibody Formation in Patients With Late Stage Renal Allograft Failure: The Everolimus-Transplant Exit Strategy Trial.

Trial Profile

Zortress (Everolimus) to Prevent Alloantibody Formation in Patients With Late Stage Renal Allograft Failure: The Everolimus-Transplant Exit Strategy Trial.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2015

At a glance

  • Drugs Everolimus (Primary) ; Calcineurin inhibitors
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms E-TEST
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2015 Planned End Date changed from 1 Jan 2017 to 1 May 2014, as reported by ClinicalTrials.gov.
    • 05 Jun 2015 Planned primary completion date changed from 1 Jan 2016 to 1 May 2014, as reported by ClinicalTrials.gov.
    • 05 Jun 2015 Status changed from suspended to discontinued, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top